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Abstract
Purpose: Prostate cancer is a bimodal disease with aggressive and indolent forms. Current prostate-specific-antigen testing
and digital rectal examination screening provide ambiguous results leading to both under-and over-treatment. Accurate,
consistent diagnosis is crucial to risk-stratify patients and facilitate clinical decision making as to treatment versus active
surveillance. Diagnosis is currently achieved by needle biopsy, a painful procedure. Thus, there is a clinical need for a
minimally-invasive test to determine prostate cancer aggressiveness. A blood sample to predict Gleason score, which is
known to reflect aggressiveness of the cancer, could serve as such a test.
Materials and Methods: Blood mRNA was isolated from North American and Malaysian prostate cancer patients/controls.
Microarray analysis was conducted utilizing the Affymetrix U133 plus 2?0 platform. Expression profiles from 255 patients/
controls generated 85 candidate biomarkers. Following quantitative real-time PCR (qRT-PCR) analysis, ten disease-associated
biomarkers remained for paired statistical analysis and normalization.
Results: Microarray analysis was conducted to identify 85 genes differentially expressed between aggressive prostate cancer
(Gleason score $8) and controls. Expression of these genes was qRT-PCR verified. Statistical analysis yielded a final seven-
gene panel evaluated as six gene-ratio duplexes. This molecular signature predicted as aggressive (ie, Gleason score $8)
55% of G6 samples, 49% of G7(3+4), 79% of G7(4+3) and 83% of G8-10, while rejecting 98% of controls.
Conclusion: In this study, we have developed a novel, blood-based biomarker panel which can be used as the basis of a
simple blood test to identify men with aggressive prostate cancer and thereby reduce the overdiagnosis and overtreatment
that currently results from diagnosis using PSA alone. We discuss possible clinical uses of the panel to identify men more
likely to benefit from biopsy and immediate therapy versus those more suited to an ‘‘active surveillance’’ strategy.
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Introduction
Prostate cancer is the most common form of cancer in men in
the United States (after skin cancer) [1]. Screening for the disease
is usually by digital rectal examination (DRE) and prostate-specific
antigen (PSA) assay. However, the benefits of PSA/DRE screening
are controversial, due to the high false positive rate, low positive
predictive value (PPV) and reported poor accuracy in identifying
men affected by aggressive prostate cancer. In the past few years,
two large prospective trials from the United States and Europe
have highlighted the ambiguity in the value of PSA-based methods
for prostate cancer screening. The Prostate, Lung, Colon and
Ovarian Cancer Screening Trial (PLCO) in the U.S. enrolled
more than 76,000 men randomized to receive yearly PSA
screening for six years and DRE for four years versus ‘‘usual
care’’ [2]. The authors found no difference in carcinoma of
prostate (CaP)-related mortality between the two groups. The
European Randomized Study of Screening for CaP (ERSPC)
Trial included 182,000 men between the ages of 50–74 years [3].
Although the authors reported a 20% reduction in CaP mortality
in men who underwent PSA testing at least once every four years,
this mortality reduction proved costly – for every one CaP death
prevented, 1,410 men needed to be screened annually and 48 men
needed treatment. These trials have reinvigorated the debate over
the utility and limitations of PSA screening [4–10].
Major problems in PSA testing arise as a result of over- and
under-diagnosis. Some 15% of men whose PSA levels are regarded
as normal (4?0 ng/mL or less), do in fact harbour prostate cancer,
including high-grade carcinoma [9]. By increasing the limit to a
level considered clinically borderline (4?0 –10?0 ng/mL), some
25% of men are found to be affected by prostate cancer [2].
Conversely, high PSA levels are observed in many men with
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in 40% to 50% of cases. Furthermore, many non-malignant
conditions may affect PSA, including benign prostate enlargement
and prostatitis. Confirmation of diagnosis requires some 12–18
core biopsies, at considerable cost and morbidity [12]. In light of
these PSA-related challenges, it is evident that there is need for
more clinically relevant biomarkers that are able to accurately
predict the presence of aggressive prostate cancer.
A recent retrospective study identified a tissue-based mRNA
expression signature of Gleason grade for predicting lethal prostate
cancer [13]. Similar biomarkers, but blood-based and capable of
identifying high-grade prostate cancer [Gleason score 7(4+3)–10]
at an early stage (prior to decision on biopsy), would be clinically
useful [14,15]. Such a technique would complement current
methodologies and help increase confidence in prostate cancer
diagnosis and management.
In earlier work, we developed a novel blood-based biomarker
panel able to risk- stratify patients for colorectal cancer [16]. The
results of this test enable clinicians to encourage with greater
confidence those patients with ‘‘high current risk‘‘ scores to
proceed with colonoscopy. Here we identify novel blood-based
biomarkers for high-grade [Gleason score 7(4+3)–10] prostate
cancer that can be used to risk-stratify PSA-positive men. This test
could be useful to identify the subgroup of men for whom the
benefit of biopsy is likely to outweigh the associated risk and
discomfort.
Men with clinically localized low grade tumors are often advised
to undergo surveillance rather than active treatment for a disease
that is unlikely to progress. However, Borocas and colleagues have
shown that fewer than 10% of men prefer surveillance over active
treatment [17]. One suggested explanation for this is that even in
low-risk men, the fear exists that a life-threatening, high grade
cancer might be missed [18,19]. A test that can predict the
presence of potential high grade tumors might relieve patient
anxiety, resulting in higher tolerance for surveillance.
Materials and Methods
Patients and blood samples
Sample acquisition for biomarker identification was conducted
between 2004 and 2009 in urology clinics across North America
(Toronto, Ontario, Canada and Boston, MA, USA) and Asia
(Penang, Malaysia). Written, informed consent was obtained from
all participants and approved by each institution’s Research Ethics
Board [Partners Health Care Institutional Review Board (Brigham
and Women’s Hospital, Boston), University Health Network
Research Ethics Board (Sunnybrook Hospital, Toronto), and Joint
Ethics Committee of School of Pharmaceutical Sciences (USM
Hospital Lam Wah Ee on Clinical Studies (Penang)].
All blood samples were taken prior to any treatment or biopsies.
Diagnosis was confirmed by transrectal ultrasound guided tru-cutH
needle biopsy and/or by histopathological findings in radical
prostatectomy specimens (See Appendix S1). When a sample had
a radical prostatectomy report, the ultimate grade was based on
the prostatectomy report. The number of core samples taken at
biopsy was 6+6 for prostate volume ,40 grams and 7+7 for
volume .40 grams. Each institution’s in-house pathologists
determined diagnosis and evaluation of Gleason score. Cases with
Gleason score =7 were excluded from the training dataset to
control for gene expression differences of intermediate grade
prostate cancer with Gleason score 7(3+4) which, we hypothesized,
could be significantly different than more aggressive Gleason score
7(4+3) [14,15]. Samples having Gleason score $ 8 at biopsy with
or without prostatectomy were specifically selected for analysis and
development of the gene signature with the training dataset. The
model developed with the Gleason score $ 8 was then later
applied to the patients with Gleason score 7 to determine if the
molecular signature could differentiate between 7(3+4) versus
more aggressive 7(4+3) Gleason scores.
In total, we collected 1,938 samples including 739 Prostate
Cancer (PrCa) cases and 1,199 controls (G0). From this group, a
255 sample subset (n=91 PrCa with Gleason score $ 8 and
n=164 controls) collected in EDTA tubes was set aside in an
initial study for biomarker discovery on a microarray platform.
Samples in each group were matched for age, race, BMI, and
comorbidities (Table 1).
For qRT-PCR verification studies, we tested the identified genes
on most of the same samples hybridized for gene identification.
We used 245 samples (G8=54, G0=191) for our Cohort I study,
182 samples (G8 n=80 and controls n=102) for our Cohort II
study and 121 samples (G8 n=64 and controls n=57) as an
independent test set for our Cohort III study (Figure 1). A Cohort
IV group of cases with intermediate grade cancer (G6 n=33,
G7(3+4) n=35, and G7(4+3) n=43) was used to evaluate cancer
aggressiveness performance.
Samples were excluded from analysis if an individual was
determined to have had: 1) previous PrCa; 2) precancerous lesions,
such as high-grade prostate intraepithelial neoplasm and atypical
small acinar proliferation; 3) history of any cancer; and/or 4)
severe medical conditions precluding treatment for prostate
cancer, such as heart or renal failure.
Patients were divided into subgroups based on Gleason scores:
G6 (Gleason score # 6); G7 (Gleason score =7); G8 (Gleason
score $ 8); and controls (G0). The North American control group
comprised urology clinic patients with a single negative biopsy.
The Malaysian control group consisted of men aged 50–75 years,
negative for DRE, and whose PSA levels were below 2?5 ng/ml
for five consecutive years, up to and including the date of
recruitment. This extra condition effectively aligns the Malaysian
controls with the North American yearly PSA screening standard.
This also allowed us to ensure that PSA velocity remained below
0?4 ng/ml/yr, reducing the probability of missed carcinomas to a
negligible value.
Blood collection and RNA isolation
For microarray analysis and Cohort I, samples of peripheral
whole blood (2610 ml) were collected in EDTA VacutainerH
tubes (Becton Dickinson) (to avoid the high globin transcript
problem on Affymetrix microarrays associated with the PAXgene
system), and processed as described previously [20].
Samples were run on the Affymetrix U133 Plus 2.0 platform.
Confirmational analysis was conducted using qRT-PCR for
Cohort II and Cohort III. For qRT-PCR, blood collected in
PAXgene
TM tubes (PreAnalytiX) was processed according to
PAXgene
TM Blood RNA Kit protocol. The PAXgene system is
more suitable for RT-PCR studies, and is a better fit for real-life
clinical applications, due to its ability to immediately stabilize
RNA and to keep it stable over a longer period of time, thereby
providing greater flexibility in sample collection and transport.
RNA integrity was assessed using the 2100 Bioanalyzer RNA
6000 Nano Chip (Agilent Technologies). All samples met the
following quality criteria: RIN$7?0; 28S:18S rRNA ratio $ 1?0;
and a validated Agilent bioanalyzer scan. RNA quantity was
determined by absorbance at 260 nm in a DU-640 Spectropho-
tometer (Beckman Coulter).
Biomarkers of Prostate Cancer
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Microarray data mining to identify aggressive prostate cancer
biomarkers involved two analyses simultaneously carried out at our
North American (Toronto, Canada) and Asian sites (Penang,
Malaysia). At the North American site, we hybridized 166 samples
(G8 n=42; G0 n=124). Genes identified as significant (p,0.05, fold
change $1.0, Benjamini-Hochberg FDR corrected) were selected for
further downstream study using annotations and probe design,
[available at the Affymetrix website (http://www.affymetrix.com)]
and information on gene structure and function [available at Nation-
al Institutes of Health website (http://www.ncbi.nlm.nih.gov)].
Table 1. Clinical characteristics of the patient cohorts for microarray hybridization.
North American Site Asian Site
Characteristics Non-cancer (G0) Prostate Cancer
(G8)
P value* Characteristics Non-cancer
(G0)
Prostate Cancer
(G8)
P value*
No. of Samples 124 42 No. of Samples 40 49
Age (median) 67 71 0.23 Age (median) 65.5 73 0.0001
BMI (median) 26.24 26.6 0.53 BMI (median) NA NA
Family History (%) 13 (10.5%) 4(9.5%) 1.00 Family History (%) 0 0 1.00
Ethnicity [no. (%)] Ethnicity [no. (%)]
White 104 (83.9) 32 (76.2) 0.26 Chinese 29 (72.5%) 35 (71.4%) 1.00
Asian 11 (8.9) 5 (11.9) 0.38 Indonesian 4 (10.0%) 5 (10.2%) 1.00
doi:10.1371/journal.pone.0045802.t001
Figure 1. Gene identification and validation process. Gene Identification using Affymetrix U133Plus 2.0 GeneChip oligonucleotide arrays was
carried out in Toronto, Canada, and Penang, Malaysia, in parallel. In Toronto, analysis was conducted on 166 samples (G8=42, G0=124). At the
Malaysian site, 89 samples were profiled (49 G8, 40 G0). From microarray data analysis, 85 genes identified at both sites were tested in a series of
quantitative real-time PCR verification studies. Twenty genes were verified through a Cohort I study on several cohorts of EDTA samples (total 245).
These 20 genes were further tested in a Cohort II series of experiments on PAXgene samples (total 182), executed independently in Penang, Malaysia.
10 of the genes were verified, of which 7 genes became our final biomarkers and also confirmed in another independent sample set-Cohort III test
(total 121).
doi:10.1371/journal.pone.0045802.g001
Biomarkers of Prostate Cancer
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Asian site in Malaysia with 89 samples (G8 n=49; G0 n=40), see
Figure 1.
Microarray data files for the combined 91 G8 and 164 G0
samples were background corrected via GCRMA and imported
into GeneSpring software (version 7?3?1, Agilent, California, USA)
for analysis. Unreliable signals, as defined by the cross-gene error
model, were discarded from analysis.
Probe set signal intensities were compared between disease and
control groups. Genes were determined to be differentially
expressed between cases and controls using the Analysis of
Variance (ANOVA) test incorporated in GeneSpring. Probesets
with p-values less than 0?05 and fold change magnitudes greater
than 1?2 were identified as statistically significant. Sample size was
determined based on an estimation we had made for a previous
study, that is, that 100 samples per group are required to achieve
adequate power (0.80), with a type I error of less than 0.05 and a
fold change magnitude greater than 1.2, for a large proportion
(over 75%) of genes being investigated [20].
Microarray data were also processed by MAS5. Probe sets
marked as ‘‘absent’’ or ‘‘marginal’’ in any sample were discarded.
The analysis was performed independently using the R program
provided by Bioconductor.org (Seattle, Washington, USA). Only
genes that appeared statistically significant in both collection sites
were selected.
Quantitative real-time polymerase chain reaction
Genes selected from the microarray analyses were verified using
qRT-PCR in a Cohort I study. Only genes identified in
microarray analysis that also remained statistically significant in
the Cohort I qRT-PCR study were retained for further
downstream analysis.
cDNA template for qRT-PCR was reverse-transcribed from
RNA using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). 20 ng of cDNA were used in a 25 mL
reaction volume in a TaqManH Duplex Reaction (for an overview
of the methodology, see Figure 1).
Genes verified in Cohort I were then tested in a Cohort II study.
Cohort II blood samples were collected in PAXgene
TM tubes
(PreAnalytiX), otherwise Cohort I and II study methodologies
were identical.
The experiments were performed in duplex qRT-PCR tests.
Each gene of interest was assayed in a series of experiments, with
an endogenous reference gene (ACTB; beta actin). Baseline
expression of ACTB allowed us to identify significantly differing
levels of gene transcripts between the prostate cancer and control
groups. Genes verified by both cohort analyses were combined as
pairs; ratios of an overexpressed gene and an underexpressed gene
were directly measured in duplex reactions. Gene expression
differences were estimated using the comparative cycle threshold
(Ct) method of relative quantification [21], normalizing the Ct
values relative to the reference gene. This was performed by
calculating a DCtsample =C t (target gene) –C t (partner gene). The
relative fold-change (disease versus control) was represented as
2
2DDCt, where DDCt = mean DCtCa – mean DCtcontrol.
We chose SAMSN1, an overexpressed gene, as the partner gene
with each of the six downregulated target genes. This format
allows calculation of an ‘‘UP/DOWN’’ gene expression ratio
between each underexpressed PrCa biomarker gene and its duplex
partner, SAMSN1, from the difference of their Ct values as
described previously [16]. A nonparametric Mann-Whitney test
evaluated statistical significance of differences between control and
PrCa mRNA levels.
Table 2. High grade prostate cancer (Gleason score 8 and above) biomarker gene list and differential expression ratio in Cohort II
verification sample set (80 disease and 102 controls).
Gene
Name# Description Sequence Accession ID
Expression Fold
Change{
Expression P
Value{ Expression AUC*
CRTAM cytotoxic and regulatory T cell molecule NM_019604 1.58 3.46E-05 0.67
CXCR3 chemokine (C-X-C motif) receptor 3 NM_001504 1.59 3.38E-05 0.66
FCRL3 Fc receptor-like 3 NM_052939 1.61 2.85E-06 0.69
KIAA1143 KIAA1143 NM_020696 1.44 1.82E-07 0.73
KLF12 Kruppel-like factor 12 NM_007249; NM_016285 1.66 8.16E-07 0.71
TMEM204 transmembrane protein 204 NM_024600 1.52 8.40E-05 0.67
SAMSN1 SAM domain, SH3 domain and nuclear
localization signals 1
NM_022136 – – –
# The 7 biomarkers were picked up from the 10 that were verified in Cohort II samples, using gene-ratio algorithm, based on the best AUC of combined gene-pair.
{Determined by qRT-PCR analysis using SAMSN1 as a partner gene, gene ratio was calculated using delta delta Ct calculation.
{Calculated by Mann-Whitney test.
*area under receiver-operating-characteristic curve.
doi:10.1371/journal.pone.0045802.t002
Figure 2. PCR data from a sample set of 122 PAXgene samples
of prostate cancer from the G8 group and 138 PAXgene
samples from the control group were performed in a 100062-
fold cross-validation test. Histograms of AUC were plotted and
compared; results showed AUCs from the PCR data were well separated
from the null sets, with an overlap of less than 5%.
doi:10.1371/journal.pone.0045802.g002
Biomarkers of Prostate Cancer
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From Cohort I (combined North American and Malaysian
study sites) 85 genes were identified to be significantly differentially
expressed between Gleason score $8 prostate cancer and controls,
and selected for further investigation via qRT-PCR (Figure 1).
Quantitative real-time PCR verification
These 85 genes were tested on 245 Cohort I samples collected in
EDTA tubes (G8 n=54; G0 n=191). Twenty of the genes were
verified as remaining significant in a qRT-PCR assay and retained
for the Cohort II study.
Of the 20 candidate genes, ten remained significant in Cohort II
samples collected in Paxgene tubes (p-value , 0.001, fold changes
from 1?31 to 1?58 for overexpressed genes and -1?28 to -1?48 for
underexpressed genes).
The expression values of the ten genes were analyzed using a
multivariate logistic regression model. The AUC ROC of each
single gene ranged from 0?60 to 0?69; paired comparison resulted
in seven-, eight- or nine-gene combinations that all achieved an
AUC of about 0?82. Of interest, the best seven-gene combination
was comprised of one overexpressed gene and six underexpressed
genes (AUC=0?82). Thus we selected this seven-gene biomarker
panel for detecting high-grade prostate cancer (Table 2).
We used the single overexpressed gene, SAMSN1, to be the
common partner gene for each of the six underexpressed genes:
CRTAM, CXCR3, FCRL3, KIAA1143, KLF12 and TMEM204.
The six duplexes representing six gene expression ratios were
evaluated on the same Cohort II samples (G8, n=80; Ctrl,
n=102). The expression levels of the six duplexes were observed
to differ significantly between disease and control groups
(p,0.0001 and fold changes of 1?44–1?66; Table 2). Discrimina-
tive performance was also evaluated using AUC ROC The
discriminative ability of the six duplex panel (combinative
performance of the six duplexes) achieved an AUC of 0?74
(95%CI: 0?67–0?80), specificity of 84%, sensitivity of 63% and
accuracy of 75%.
To estimate the possibility that the results were due merely to
random chance, we performed two-fold cross-validations, in which
half of the samples were used to define coefficients and thresholds
for the model, which was then used to predict the remaining half
of the samples. This process was iterated 1000 times using the
actual data, first with the aggressive cancer status and a second
time with the status randomly re-assigned. The distribution of the
AUC ROC from each analysis resulted in two well-separated
curves with less than 5% overlap from which we conclude that the
observed performance is unlikely to be merely the result of random
chance (Figure 2).
From the data, we built a logistic regression model combining
PSA and gene expression ratios using G8 samples against controls
to further enhance the discriminative ability of the panel. This
achieved an AUC ROC of 0.99 on 69 G8 versus 101 controls of
Cohort II (sensitivity = 96%, specificity = 100%).
This combined panel of PSA and gene expression ratios (see
Table 3) defined from Cohort II was tested on Cohort III samples.
All six duplexes remained significantly differentially expressed
between G8 and controls (all p-values are # .01). The equation
built from the Cohort II study – with fixed parameters – was
Table 3. Combined PSA and mRNA model.
Constant CRTAM CXCR3 FCRL3 KIAA1143 KLF12 TMEM204 Log2PSA
22.83 0.208 20.729 0.752 20.779 3.77 0.427 3.22
Inputs are CT values for genes and Log2 transformation of PSA in ng/ml.
doi:10.1371/journal.pone.0045802.t003
Figure 3. Predictions for independent Cohort III and Cohort IV samples. The negative prediction rate for control cases is charted along with
the positive prediction rates for cancer cases. PSA alone has high positive predictive rates for all cancer grades (.87%) but the combined PSA and
RNA panel has lower positive prediction rates for the less aggressive G6 and G7(3+4) subgroups, 55%, and 49% respectively) while nearly the same
positive prediction rate for the more aggressive G7(4+3) as G8 groups (79% and 83% respectively.
doi:10.1371/journal.pone.0045802.g003
Biomarkers of Prostate Cancer
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evaluation of the differential performance of the biomarker panel.
The AUC ROC was 0.88 on 54 G8 versus 57 controls (sensitivity
= 83%, specificity = 98%).
All analyses reported above involved samples of controls or G8
cases and were used for model validation. However, the objective
in this study was to estimate aggressiveness of the cancer. For this
purpose we used Cohort IV, a set comprising cases of intermediate
cancer grades (G6 n=33, G7(3+4) n=35, and G7(4+3) n=43).
For this analysis, control, G6 and G7(3+4) cases were considered
non-aggressive cancers and G7(4+3) and G8 were considered
aggressive cancers. ROC analysis (as applied for Cohorts I,II,III) is
not appropriate here, as ROC calculation is best for simple
positive and negative proportions within groups, and Cohort IV
contained more complex subgroupings.
Instead, for Cohort IV analysis, we evaluated the positive
prediction rate for each subgroup, and found that 55% of G6,
49% of G7(3+4) and 79% of G7(4+3) were detected with the same
signature that had identified the G8 aggressive cancer cases
(Figure 3). By contrast, PSA level alone was unable to differentiate
between the less aggressive G6, G7(3+4) and the more aggressive
G7(4+3) groups, yielding positive prediction rates of 88%, 89%
and 100%, respectively, in samples where PSA levels reached
4 ng/ml.
Discussion
Our objective in this study was to identify blood-based
biomarkers for aggressive prostate cancer. We collected samples
at several locations, from both Asian and non-Asian subjects, in
order to minimize ethnic and racial differences. Our strategy
focused mainly on the identification of biomarkers for the highest-
grade cancers (Gleason score 8–10), and we then applied the
model to patients with Gleason score 7(4+3), Gleason score 7(3+4),
Gleason score 6 and controls. The model was successful in
distinguishing patients with high risk Gleason score 7(4+3) to
Gleason score 10 from those with low to intermediate risk Gleason
score 6 and Gleason score 7(3+4). The preliminary results of this
seven gene model to predict aggressive prostate cancer are
encouraging and need to be validated in a multi-site validation
clinical study.
As confirmed in the results above, PSA on its own has a high
positive prediction rate. The addition of the reported blood-based
biomarker panel improved PSA accuracy for aggressive cancers.
This was achieved by correcting for over-diagnosis of aggressive
cancers in the G6 and G7 cohorts by about one-half (fewer cases
should be expected to exhibit an aggressive cancer molecular
signature in the lower-grade cancer cohorts).
We identified candidate biomarker genes and developed gene
duplexes by combining an overexpressed gene with an under-
expressed gene in order to amplify differential gene expression and
normalize for individual variations (Table 2). Verification on
independent Cohort III samples showed that we were successful in
our efforts. This is represented by our analysis in control patients
and confirmed Gleason score 8–10 prostate cancer patients, with a
specificity of 80% or better. A gene-only multivariate predictive
model built on Cohort II data was applied to Cohort III samples,
and the specificity remained high at 83%.
The seven genes identified from blood-derived mRNA in this
study are mainly involved in immune response, chemotaxis, and
gene transcription regulation in carcinogenesis [22–25]. Of
interest, our study found CRTAM significantly underexpressed
in aggressive prostate cancer, suggesting a possible role for T-cell
deficiency in prostate cancer. In addition, altered KLF expression
has been found in tumors and tumor progression [26–29], and
several investigations report that activator protein 2 alpha (AP-
2alpha) plays an essential role in tumorigenesis [30,31].
Many men with early prostate cancer will never progress to late
stage cancer. The subset of men with indolent disease would be
excellent candidates for active surveillance. However, there is a
lack of clear criteria to differentiate between those most at risk for
aggressive cancer and those whose disease will follow an indolent
course [4,32,33]. PSA as a lone indicative biomarker has a high
false positive and significant false negative rate [34]. It exposes
many men to repeated unnecessary biopsies, with risks of pain,
infection, sepsis, and potential cascading downstream consequenc-
es, such as radical prostatectomy with side-effects of impotence
and incontinence [35]. Thus an important clinical challenge in
prostate oncology is to identify, within the population of PSA-
positive men, those with high-grade or aggressive cancer, without
requiring all patients to undergo a painful tissue biopsy.
The blood-based biomarker signature reported here identifies
prostate cancers with Gleason scores between 7(4+3) and 10.
Replicated in a more generalized and representative population,
this biomarker signature can be refined and used to form the basis
of a simple blood test. Used in conjunction with PSA as a risk
stratification tool, the reported signature can identify men at risk of
having high-grade prostate cancer. Biopsy, saturation biopsy,
confirmation and intervention can be recommended for men of
this category, as treatment for higher-grade cancer has been
shown to positively affect 5-year survival rates as compared with
observation [36]. Conversely, men without this biomarker
signature may have more confidence in choosing ‘‘active
surveillance’’ over immediate therapy.
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